Facility Details

Core provides in vitro HIV-1 neutralizing antibody assay services. Serves as resource for assessing breadth and potency of HIV-1 neutralizing antibodies, and for characterizing neutralization phenotype of HIV-1 isolates. Investigators send monoclonal antibodies or serum samples from vaccinated or HIV-1-infected individuals to the core for in vitro testing using the validated TZM.bl neutralizing antibody assay. The core also has the capability to phenotype primary HIV-1 isolates for sensitivity to broadly neutralizing antibodies. GCLP-compliant, In vitro testing of monoclonal antibodies or seurm samples, Validated TZM.bl neutralizing antibody assay, Phenotoyping of primary HIV-1 isolates.